Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection |
| |
Authors: | Tao Lu Wai-Kay Seto Ran-Xu Zhu Ching-Lung Lai Man-Fung Yuen |
| |
Institution: | Tao Lu, Wai-Kay Seto, Ran-Xu Zhu, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, Guangdong Province, ChinaWai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China |
| |
Abstract: | Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with the majority of cases associated with persistent infection from hepatitis B virus (HBV) or hepatitis C virus (HCV). Natural history studies have identified risk factors associated with HCC development among chronic HBV and HCV infection. High-risk infected individuals can now be identified by the usage of risk predictive scores. Vaccination plays a central role in the prevention of HBV-related HCC. Treatment of chronic HBV infection, especially by nucleoside analogue therapy, could also reduce the risk of HBV-related HCC. Concerning HCV infection, besides the advocation of universal precautions to reduce the rate of infection, pegylated interferon and ribavirin could also reduce the risk of HCV-related HCC among those achieving a sustained virologic response. Recently there has been mounting evidence on the role of chemopreventive agents in reducing HBV- and HCV-related HCC. The continued advances in the understanding of the molecular pathogenesis of HCC would hold promise in preventing this highly lethal cancer. |
| |
Keywords: | Hepatitis B virus Hepatitis C virus Hepatocellular carcinoma Vaccination Prevention |
本文献已被 维普 等数据库收录! |
| 点击此处可从《世界胃肠病学杂志(英文版)》浏览原始摘要信息 |
|